Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of glucagon-like peptide-1
(GLP-1) analogue liraglutide in the treatment of acute minor stroke (National Institute of
Health stroke scale, NIHSS ≤ 3) or high-risk transient ischemic attack (TIA) (ABCD2 score ≥ 4
) patients with type 2 diabetes mellitus.